FluGen raises $12M round for universal flu vaccine

Madison, WI-based FluGen has raised a $12 million Series A from Venture Investors LLC, the Wisconsin Alumni Research Foundation, the State of Wisconsin Investment Board as well as existing investors led by Knox LLC. The money will fund the first human studies of REDEE FLU, a universal flu vaccine candidate. Dan Stinchcomb, the co-founder of Inviragen, and C. Boyd Clarke were named independent directors. "This financing provides the resources necessary to complete preclinical testing, and to assess the safety and immune responses induced by REDEE FLU in a Phase I clinical trial of the vaccine," said CEO Paul V. Radspinner. Release

Suggested Articles

I-MAB's anti-GM-CSF drug works "upstream" in inflammation pathways, potentially blocking several dangerous cytokines in COVID-19, executives…

Antibe's lead drug beat placebo at reducing osteoarthritis pain, boosting its case as an alternative to NSAIDs, commonly used to treat the condition.

The trial marks the start of a new phase of the response to SARS-CoV-2 in which people will receive drugs designed specifically for the virus.